Relationship between the action of monoamine oxidase inhibitors on the noradrenaline uptake system and their antidepressant efficacy.
D000818:Animals; D000928:Antidepressive Agents / Q000627:therapeutic use*; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism*; D002540:Cerebral Cortex / Q000378:metabolism; D003864:Depression, Chemical; D005260:Female; D066298:In Vitro Techniques; D007490:Iproniazid / Q000494:pharmacology*; D007520:Isocarboxazid / Q000494:pharmacology*; D008680:Metaraminol / Q000378:metabolism; D008995:Monoamine Oxidase / Q000378:metabolism; D009526:Nialamide / Q000494:pharmacology*; D009638:Norepinephrine / Q000378:metabolism*; D010293:Pargyline / Q000494:pharmacology*; D010624:Phenelzine / Q000494:pharmacology*; D051381:Rats; D014191:Tranylcypromine / Q000494:pharmacology*; D014316:Tritium
D000928:Antidepressive Agents; D014316:Tritium; D007520:Isocarboxazid; D014191:Tranylcypromine; D008680:Metaraminol; D010293:Pargyline; D007490:Iproniazid; D008995:Monoamine Oxidase; D010624:Phenelzine; D009526:Nialamide; D009638:Norepinephrine